2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Alpha-particle Nanotherapeutics against Recurrent, Chemo-resistant Triple Negative Breast Cancer

Ottawa, ON, Canada (UroToday.com) The challenge for delivering radiation to large tumors like Triple Negative Breast Cancer is penetration into the core of the tumor. Traditional targeted alpha therapy delivers the radioisotope to a receptor on the tumor surface, so the short range of the alpha particle means that little radiation penetrates very far into the tumor.

This study looks at the use of small liposomes attached to Ac225. The liposome diffusively penetrates the tumor. The Ac225 is released in the high-pH environment of the tumor interior. In an HER2-negative mouse model, interstitially-releasing 225Ac-loaded liposomes resulted in the longest overall and median survival.


Presented by: Professor Stavroula Sofou, Associate Professor, Chemical and Biochemical Engineering, Rutgers University, Piscataway, New Jersey, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada